Forecast
The analysts' average price target is €20.15 (+15.01%). The median is €17.32 (-1.14%).
| Buy |
16 |
| Hold |
19 |
| Sell |
5 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, Intercept Pharmaceuticals had revenue of €266.35m and net profit of €107.37m
| (EUR) | 2022 | YoY |
|---|---|---|
| Revenue | 266.35m | 16.67% |
| Gross profit | 265.44m | 16.24% |
| Net profit | 107.37m | 184.19% |
| EBITDA | -142.52m | 376.27% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €724.24m |
Number of shares | 41.83m |
52-week high/low | €19.92 - €8.04 |
| Dividends | No |
Beta | 0.88 |
P/E ratio | 5.57 |
PEG ratio | -0.04 |
P/B ratio | 6.90 |
P/S ratio | 2.78 |
Company profile
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
| Name | Intercept Pharmaceuticals |
| CEO | Jerome B. Durso |
| Headquarters | New York City,
ny USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 11/10/2012 |
| Employees | 341 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ICPT |